Valuation: AstraZeneca Pharma India Limited

Market Cap 194B 2.03B 1.75B 1.65B 1.5B 2.81B 2.86B 19.28B 7.54B 97.07B 7.61B 7.45B 323B P/E 2025
186x
P/E 2026 103x
Enterprise Value 190B 1.99B 1.72B 1.62B 1.47B 2.76B 2.81B 18.94B 7.41B 95.38B 7.48B 7.32B 317B EV / Sales 2025
12.2x
EV / Sales 2026 8.38x
Free-Float
18.42%
Yield 2025
0.37%
Yield 2026 0.46%
1 day-0.49%
1 week-5.31%
Current month-4.32%
1 month-5.27%
3 months-7.14%
6 months-12.67%
Current year-13.94%
1 week 7,740
Extreme 7740
8,254.9
1 month 7,740
Extreme 7740
8,497.7
Current year 7,630
Extreme 7630
9,219.25
1 year 7,630
Extreme 7630
9,850
3 years 3,943.8
Extreme 3943.8
10,653.05
5 years 2,437.75
Extreme 2437.75
10,653.05
10 years 882.55
Extreme 882.55
10,653.05
Manager TitleAgeSince
Chief Executive Officer - 2025-06-30
Director of Finance/CFO - 2023-09-30
Compliance Officer - 2026-02-22
Director TitleAgeSince
Director/Board Member 67 2016-12-01
Chairman 52 2024-09-29
Director/Board Member - 2024-02-07
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%-5.31%-6.48%+95.54% 2.03B
-2.25%-0.47%+72.43%+119.36% 1,052B
-0.66%+0.43%+49.01%+50.11% 627B
-0.54%+1.39%+21.88%+63.83% 441B
-1.99%-3.32%+41.98%+34.08% 349B
-1.05%-2.81%+24.22%+34.67% 287B
-2.12%-3.67%-1.09%+3.11% 241B
-0.63%+1.04%+43.03%+59.10% 224B
-1.19%-3.41%-9.18%-52.41% 202B
+0.16%+3.87%+16.25%+73.27% 172B
Average -0.64%+0.02%+25.20%+48.07% 359.72B
Weighted average by Cap. -0.09%+0.31%+41.29%+62.04%

Financials

2025 2026
Net sales 17.16B 179M 155M 146M 132M 249M 253M 1.71B 667M 8.59B 674M 659M 28.56B 22.76B 238M 206M 193M 176M 330M 336M 2.26B 885M 11.4B 893M 874M 37.87B
Net income 1.16B 12.1M 10.45M 9.82M 8.93M 16.8M 17.07M 115M 45M 580M 45.44M 44.46M 1.93B 1.88B 19.61M 16.94M 15.92M 14.47M 27.21M 27.66M 186M 72.92M 939M 73.63M 72.03M 3.12B
Net Debt -5B -52.33M -45.2M -42.47M -38.63M -72.62M -73.82M -498M -195M -2.51B -196M -192M -8.33B -3.37B -35.25M -30.44M -28.61M -26.02M -48.92M -49.72M -335M -131M -1.69B -132M -129M -5.61B
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
760
Date Price Change Volume
26-08-14 ₹7,753.70 -0.49% 158
26-08-13 ₹7,791.60 -1.44% 2,216
26-08-12 ₹7,905.70 -0.51% 250
26-08-11 ₹7,946.00 -1.63% 443
26-08-10 ₹8,077.30 -1.35% 1,264
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ASTRAZEN Stock